Peter J Barnes

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. doi request reprint Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine
    Grace O Osoata
    Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK
    Chest 135:1513-20. 2009
  2. doi request reprint Cellular and molecular mechanisms of chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK Electronic address
    Clin Chest Med 35:71-86. 2014
  3. pmc Statins as potential therapeutic drug for asthma?
    Cheng Yuan
    Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China
    Respir Res 13:108. 2012
  4. ncbi request reprint New anti-inflammatory targets for chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Nat Rev Drug Discov 12:543-59. 2013
  5. doi request reprint Interview: interview with peter j barnes
    Peter J Barnes
    Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK
    Ther Deliv 4:901-3. 2013
  6. ncbi request reprint Development of new drugs for COPD
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, UK
    Curr Med Chem 20:1531-40. 2013
  7. doi request reprint Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    J Allergy Clin Immunol 131:636-45. 2013
  8. doi request reprint New drugs for asthma
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Semin Respir Crit Care Med 33:685-94. 2012
  9. pmc STAT6 expression in T cells, alveolar macrophages and bronchial biopsies of normal and asthmatic subjects
    Katsuyuki Tomita
    Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, Osaka, Japan
    J Inflamm (Lond) 9:5. 2012
  10. pmc Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial
    Brian J O'Connor
    Chiesi Farmaceutici s p a, Via Palermo 26 A, Parma, Italy
    BMC Pulm Med 11:60. 2011

Collaborators

Detail Information

Publications184 found, 100 shown here

  1. doi request reprint Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine
    Grace O Osoata
    Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK
    Chest 135:1513-20. 2009
    ..Nitrative stress is implicated in COPD pathogenesis, but PN has not been detected due to a short half-life (< 1 s) at physiologic condition. Instead, 3-nitrotyrosine has been measured as a footprint of PN release...
  2. doi request reprint Cellular and molecular mechanisms of chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK Electronic address
    Clin Chest Med 35:71-86. 2014
    ..Systemic inflammation may worsen comorbidities. Treatment of pulmonary inflammation may therefore have beneficial effects. ..
  3. pmc Statins as potential therapeutic drug for asthma?
    Cheng Yuan
    Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China
    Respir Res 13:108. 2012
    ..The aim of this study is to determine whether statins are beneficial for asthma administration, and explore the potential covariables that may affect their clinical effectiveness...
  4. ncbi request reprint New anti-inflammatory targets for chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Nat Rev Drug Discov 12:543-59. 2013
    ....
  5. doi request reprint Interview: interview with peter j barnes
    Peter J Barnes
    Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK
    Ther Deliv 4:901-3. 2013
    ..Interview conducted by Hannah Coaker, Assistant Commissioning Editor. ..
  6. ncbi request reprint Development of new drugs for COPD
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, UK
    Curr Med Chem 20:1531-40. 2013
    ..Thus although there have been major advances in the development of long-acting bronchodilators for COPD, it has proved difficult to find anti-inflammatory treatments that are safe and effective...
  7. doi request reprint Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    J Allergy Clin Immunol 131:636-45. 2013
    ..Identifying the molecular mechanisms of steroid resistance in asthmatic patients and patients with COPD can thus lead to more effective anti-inflammatory treatments...
  8. doi request reprint New drugs for asthma
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Semin Respir Crit Care Med 33:685-94. 2012
    ..Improved immunotherapy approaches have the potential for disease modification, although prospects for a cure are currently remote...
  9. pmc STAT6 expression in T cells, alveolar macrophages and bronchial biopsies of normal and asthmatic subjects
    Katsuyuki Tomita
    Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, Osaka, Japan
    J Inflamm (Lond) 9:5. 2012
    ..abstract:..
  10. pmc Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial
    Brian J O'Connor
    Chiesi Farmaceutici s p a, Via Palermo 26 A, Parma, Italy
    BMC Pulm Med 11:60. 2011
    ..The aim was to assess the onset of the anti-inflammatory action of low and high doses and evaluate the suitability of non-invasive assessments to demonstrate dose response...
  11. doi request reprint Severe asthma: advances in current management and future therapy
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    J Allergy Clin Immunol 129:48-59. 2012
    ..Finally, several subtypes of severe asthma are now recognized, and in the future, it will be necessary to find biomarkers that predict responses to specific forms of therapy...
  12. pmc Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review
    Hannu Kankaanranta
    The Immunopharmacological Research Group, Medical School, University of Tampere, Tampere, Finland
    Respir Res 5:17. 2004
    ..However, addition of LABA and LTRA may be equal with respect to asthma exacerbations. However, more and longer studies are needed to better clarify the role of LTRAs and theophylline as add-on therapies...
  13. pmc Pharmacology of airways and vessels in lung slices in situ: role of endogenous dilator hormones
    L Moreno
    Cardiothoracic Pharmacology, and Airway Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street SW3 6LY, UK
    Respir Res 7:111. 2006
    ..Our observations are the first to identify mechanisms of endothelium dependent dilations in precision cut lung slices and the potential for transverse hormonal communication between airways and vessels...
  14. pmc Exhaled carbon monoxide in asthmatics: a meta-analysis
    Jingying Zhang
    Department of Respiratory Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    Respir Res 11:50. 2010
    ..The purpose of this meta-analysis is to determine whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control...
  15. pmc Exhaled 8-isoprostane in childhood asthma
    Sukhbir K Shahid
    National Heart and Lung Institute, Imperial College London, London, UK
    Respir Res 6:79. 2005
    ..Exhaled breath condensate (EBC) is a non-invasive method to assess airway inflammation and oxidative stress and may be useful in the assessment of childhood asthma...
  16. pmc Epigenetics and airways disease
    Ian M Adcock
    Airways Disease Section, National Heart and Lung Institute, Imperial College London, UK
    Respir Res 7:21. 2006
    ..These changes, despite being heritable and stably maintained, are also potentially reversible and there is scope for the development of 'epigenetic therapies' for disease...
  17. pmc Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress
    Nicolas Mercado
    Airway Disease Section, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
    Biochem Biophys Res Commun 406:292-8. 2011
    ..92, p<0.0001). Thus, reduced HDAC2 activity in COPD may account for increased Nrf2 acetylation, reduced Nrf2 stability and impaired anti oxidant defences...
  18. ncbi request reprint Theophylline in chronic obstructive pulmonary disease: new horizons
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK
    Proc Am Thorac Soc 2:334-9; discussion 340-1. 2005
    ..Better understanding of the molecular basis for the action of theophylline might lead to the development of novel drugs...
  19. ncbi request reprint Distribution of receptor targets in the lung
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
    Proc Am Thorac Soc 1:345-51. 2004
    ..Many novel receptors, including orphan receptors, have now been identified as these may be future targets for developing novel therapies for asthma and chronic obstructive pulmonary disease...
  20. ncbi request reprint Novel signal transduction modulators for the treatment of airway diseases
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Pharmacol Ther 109:238-45. 2006
    ..It is likely that modulators of signal transduction pathways may lead to the development of several novel anti-inflammatory treatments for asthma and COPD in the future...
  21. pmc Receptor heterodimerization: a new level of cross-talk
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    J Clin Invest 116:1210-2. 2006
    ....
  22. ncbi request reprint Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Expert Opin Ther Targets 9:1111-21. 2005
    ..HDACs may be inhibited directly by siRNA and in the future by small-molecule activators may be discovered through high output screening. These drugs may represent a novel approach to treating chronic inflammatory diseases...
  23. pmc How corticosteroids control inflammation: Quintiles Prize Lecture 2005
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, Section of Airway Disease, Dovehouse St, London SW3 6LY, UK
    Br J Pharmacol 148:245-54. 2006
    ..Theophylline, by activating HDAC, may reverse this corticosteroid resistance. This research may lead to the development of novel anti-inflammatory approaches to manage severe inflammatory diseases...
  24. pmc Drugs for asthma
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, SW3 6LY London
    Br J Pharmacol 147:S297-303. 2006
    ..It seems likely that pharmacology, rather than molecular genetics, will remain the main approach to the further improvement of treatment for asthma...
  25. ncbi request reprint Reduced histone deacetylase in COPD: clinical implications
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
    Chest 129:151-5. 2006
    ..This mechanism is also relevant to asthmatic patients who smoke, patients with severe asthma and cystic fibrosis, in whom oxidative stress is also increased...
  26. ncbi request reprint Corticosteroid effects on cell signalling
    P J Barnes
    Dept of Thoracic Medicine, National Heart and Lung Institute, Dovehouse St, London, SW3 6LY, UK
    Eur Respir J 27:413-26. 2006
    ..The therapeutic implications of these new findings are discussed...
  27. ncbi request reprint Pulmonary biomarkers in chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, London, UK
    Am J Respir Crit Care Med 174:6-14. 2006
    ..In the future, pulmonary biomarkers may be useful in predicting disease progression, indicating disease instability, and in predicting response to current therapies and novel therapies, many of which are now in development...
  28. ncbi request reprint Will it be steroids for ever?
    P J Barnes
    Section of Airway Disease, National Heart and Lung Institute, Imperial College, London, UK
    Clin Exp Allergy 35:843-5. 2005
  29. ncbi request reprint New treatments for chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, School of Medicine, London, United Kingdom
    Ann Ist Super Sanita 39:573-82. 2003
    ..There is also a search for elastase inhibitors to prevent the development of emphysema and drugs that may even reverse the lung destruction...
  30. ncbi request reprint Asthma guidelines: recommendations versus reality
    Peter J Barnes
    Department of Thoracic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, SW3 6LY London, UK
    Respir Med 98:S1-7. 2004
    ..Improvements in inhaled drug delivery will continue to be paramount in improving asthma management...
  31. ncbi request reprint COPD: is there light at the end of the tunnel?
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
    Curr Opin Pharmacol 4:263-72. 2004
    ..There is a need for validated biomarkers and monitoring techniques in early clinical studies with new therapies for COPD...
  32. ncbi request reprint COPD--a neglected disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Lancet 364:564-5. 2004
  33. ncbi request reprint Prospects for new drugs for chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Lancet 364:985-96. 2004
    ..Effective delivery of drugs to the sites of disease in the peripheral lung is an important consideration, and there is a need for validated biomarkers and monitoring techniques in early clinical studies with new therapies for COPD...
  34. ncbi request reprint New drugs for asthma
    Peter J Barnes
    National Heart and Lung Institute, Imperial College Faculty of Medicine, Dovehouse Street, London SW3 6LY, UK
    Nat Rev Drug Discov 3:831-44. 2004
    ..New anti-inflammatory therapies include corticosteroids and inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinase and nuclear factor-kappaB. The prospects for a curative treatment are on the horizon...
  35. ncbi request reprint The size of the problem of managing asthma
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Respir Med 98:S4-8. 2004
    ..There is no doubt that the type of inhaler is just as important as the class of drug in the long-term management of asthma. Improvements in inhaled drug delivery will continue to be important in improving asthma management...
  36. ncbi request reprint Corticosteroid resistance in airway disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK
    Proc Am Thorac Soc 1:264-8. 2004
    ....
  37. pmc Characterization of T lymphocytes in chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, United Kingdom
    PLoS Med 1:e20. 2004
  38. ncbi request reprint Alveolar macrophages in chronic obstructive pulmonary disease (COPD)
    P J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
    Cell Mol Biol (Noisy-le-grand) 50:OL627-37. 2004
    ..There are several novel therapeutic strategies targeted at macrophages...
  39. ncbi request reprint Mediators of chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, United Kingdom
    Pharmacol Rev 56:515-48. 2004
    ..The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease...
  40. ncbi request reprint Histone acetylation and deacetylation: importance in inflammatory lung diseases
    P J Barnes
    National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
    Eur Respir J 25:552-63. 2005
    ..The reduction in histone deacetylase activity can be restored by theophylline, which may be able to reverse steroid resistance in chronic obstructive pulmonary disease and other inflammatory diseases...
  41. ncbi request reprint COPD: current therapeutic interventions and future approaches
    P J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
    Eur Respir J 25:1084-106. 2005
    ..More research is needed to understand the cellular and molecular mechanisms of chronic obstructive pulmonary disease and to develop biomarkers and monitoring techniques to aid the development of new therapies...
  42. ncbi request reprint Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
    Lancet 363:731-3. 2004
    ..This hypothesis raises the possibility that novel therapeutic approaches might unlock this corticosteroid resistance, leading to more effective anti-inflammatory treatments for COPD and other severe inflammatory diseases...
  43. ncbi request reprint New therapies for asthma
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, SW3 6LY, UK
    Trends Mol Med 12:515-20. 2006
    ..Prospects for a cure are currently remote but might arise from the development of vaccines that target the aberrant immune function in asthma...
  44. doi request reprint Glucocorticoid resistance in inflammatory diseases
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 373:1905-17. 2009
    ....
  45. doi request reprint Intrinsic asthma: not so different from allergic asthma but driven by superantigens?
    P J Barnes
    National Heart and Lung Institute, Imperial College London, London, UK
    Clin Exp Allergy 39:1145-51. 2009
    ....
  46. doi request reprint The cytokine network in chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, London, United Kingdom
    Am J Respir Cell Mol Biol 41:631-8. 2009
    ....
  47. doi request reprint Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
    Proc Am Thorac Soc 6:693-6. 2009
    ....
  48. doi request reprint Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    Peter J Barnes
    Imperial College, London, UK
    Pulm Pharmacol Ther 23:165-71. 2010
    ..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
  49. doi request reprint Mechanisms and resistance in glucocorticoid control of inflammation
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    J Steroid Biochem Mol Biol 120:76-85. 2010
    ..In patients with glucocorticoid resistance alternative anti-inflammatory treatments are being investigated as well as drugs that may reverse the molecular mechanism of glucocorticoid resistance...
  50. doi request reprint Inhaled corticosteroids in COPD: a controversy
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Respiration 80:89-95. 2010
    ..In the future, alternative anti-inflammatory treatments will be needed for COPD or therapeutic strategies which reverse the molecular pathways that causes corticosteroid resistance...
  51. doi request reprint New therapies for asthma: is there any progress?
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Trends Pharmacol Sci 31:335-43. 2010
    ..Improved immunotherapy approaches have the prospect of disease modification, although prospects for a cure are currently remote. The most promising therapeutic developments for asthma are discussed in this review...
  52. doi request reprint New therapies for chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Med Princ Pract 19:330-8. 2010
    ..This might be achieved by theophylline-like drugs, phosphoinositide 3 kinase-delta inhibitors, more effective antioxidants and non-antibiotic macrolides...
  53. pmc Glucocorticosteroids: current and future directions
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Br J Pharmacol 163:29-43. 2011
    ..In patients with glucocorticoid resistance alternative anti-inflammatory treatments are being investigated as well as drugs that may reverse the molecular mechanisms of glucocorticoid resistance...
  54. doi request reprint Pathophysiology of allergic inflammation
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Immunol Rev 242:31-50. 2011
    ..Corticosteroids are highly effective with a broad spectrum of anti-inflammatory effects, including epigenetic modulation of the inflammatory response and suppression of GATA3...
  55. pmc Biochemical basis of asthma therapy
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London SW3 6LY, United Kingdom
    J Biol Chem 286:32899-905. 2011
    ..There are beneficial molecular interactions between ╬▓(2)AR and glucocorticoid-activated pathways. Understanding these signaling pathways may lead to even more effective therapies in the future...
  56. doi request reprint Systemic manifestations and comorbidities of COPD
    P J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Eur Respir J 33:1165-85. 2009
    ..Another approach is the reversal of corticosteroid resistance, for example with effective antioxidants. More research is needed on COPD comorbidities and their treatment...
  57. doi request reprint Emerging pharmacotherapies for COPD
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Chest 134:1278-86. 2008
    ..This might be achieved by theophylline-like drugs, more effective antioxidants, and nonantibiotic macrolide agents...
  58. ncbi request reprint The problem of cough and development of novel antitussives
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK
    Pulm Pharmacol Ther 20:416-22. 2007
    ..It is also likely that several novel treatments that are developed as analgesics will also prove to be beneficial in the treatment of cough...
  59. ncbi request reprint Emerging targets for COPD therapy
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Curr Drug Targets Inflamm Allergy 4:675-83. 2005
    ..Effective delivery of drugs to the sites of disease in the peripheral lung is an important consideration, and there is the need for validated biomarkers and monitoring techniques in early clinical studies with new therapies for COPD...
  60. ncbi request reprint Scientific rationale for using a single inhaler for asthma control
    P J Barnes
    Section of Airway Disease, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Eur Respir J 29:587-95. 2007
    ..There is now a strong scientific rationale for single inhaler therapy in asthma, but more research is now needed to better understand the mechanisms involved...
  61. ncbi request reprint New molecular targets for the treatment of neutrophilic diseases
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK
    J Allergy Clin Immunol 119:1055-62; quiz 1063-4. 2007
    ..Antioxidants, long-acting beta(2)-agonists, and activators of histone deacetylase may also be effective...
  62. pmc Chronic obstructive pulmonary disease: a growing but neglected global epidemic
    Peter J Barnes
    Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    PLoS Med 4:e112. 2007
  63. pmc Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London
    BMJ 335:513. 2007
  64. pmc A blood test for lung fibrosis
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, London, United Kingdom
    PLoS Med 5:e98. 2008
  65. doi request reprint Frontrunners in novel pharmacotherapy of COPD
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Curr Opin Pharmacol 8:300-7. 2008
    ..Perhaps the most promising approach is reversal corticosteroid resistance through increasing HDAC2 activity. This may be achieved by theophylline-like drugs, more effective antioxidants and non-antibiotic macrolides...
  66. ncbi request reprint Role of GATA-3 in allergic diseases
    Peter J Barnes
    Airway Diseases Section, National Heart and Lung Institute, Imperial College, London, UK
    Curr Mol Med 8:330-4. 2008
    ..Corticosteroids act as indirect inhibitors and in patients with corticosteroid resistance p38 MAP kinase inhibitors may also prove to be useful in the future...
  67. doi request reprint Role of HDAC2 in the pathophysiology of COPD
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London SW3 6LY, United Kingdom
    Annu Rev Physiol 71:451-64. 2009
    ..Antioxidants and inhibitors of nitric oxide synthesis may therefore restore corticosteroid sensitivity in COPD, but this can also be achieved by low concentrations of theophylline and curcumin, which act as HDAC activators...
  68. pmc The cytokine network in asthma and chronic obstructive pulmonary disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College London, London, UK
    J Clin Invest 118:3546-56. 2008
    ....
  69. doi request reprint Future treatments for chronic obstructive pulmonary disease and its comorbidities
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK
    Proc Am Thorac Soc 5:857-64. 2008
    ..Accelerated aging may be associates in common to COPD and several comorbidities, prompting the development of antiaging molecules, such as sirtuin 1 agonists, which may also be effective in reducing the risk of lung cancer...
  70. doi request reprint Immunology of asthma and chronic obstructive pulmonary disease
    Peter J Barnes
    Airway Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Nat Rev Immunol 8:183-92. 2008
    ..This has important implications for the development of new therapies...
  71. ncbi request reprint Chronic obstructive pulmonary disease: molecular and cellular mechanisms
    P J Barnes
    National Heart and Lung Institute, Imperial College, School of Medicine, London, UK
    Eur Respir J 22:672-88. 2003
    ..This inflammation, in marked contrast to asthma, appears to be resistant to corticosteroids, prompting a search for novel anti-inflammatory therapies that may prevent the relentless progression of the disease...
  72. doi request reprint Histone deacetylase-2 and airway disease
    Peter J Barnes
    National Heart and Lung Institute, Imperial College, London, UK
    Ther Adv Respir Dis 3:235-43. 2009
    ..In the future selective PI3Kdelta inhibitors and more direct activators of HDAC2 may be used to treat corticosteroid-resistant inflammatory diseases of the lung, including COPD, severe asthma and asthma in smokers...
  73. ncbi request reprint Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy
    Omar S Usmani
    Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Am J Respir Crit Care Med 172:704-12. 2005
    ..Together, our data confirm that GR nuclear translocation may underlie the complementary interactions between LABAs and corticosteroids, although the precise signal transduction mechanisms remain to be determined...
  74. ncbi request reprint Decreased histone deacetylase activity in chronic obstructive pulmonary disease
    Kazuhiro Ito
    Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United Kingdom
    N Engl J Med 352:1967-76. 2005
    ..HDAC is a key molecule in the repression of production of proinflammatory cytokines in alveolar macrophages...
  75. pmc Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease
    Kittipong Maneechotesuwan
    Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United Kingdom
    PLoS Med 6:e1000076. 2009
    ..We investigated the effect of the corticosteroid fluticasone propionate on GATA-3 regulation in human T-lymphocytes in vitro and in vivo...
  76. ncbi request reprint Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response
    Ian M Adcock
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Antioxid Redox Signal 7:144-52. 2005
    ..This may account for the lack of glucocorticoid sensitivity in patients with chronic obstructive pulmonary disease. Antioxidants should reduce the inflammation and restore glucocorticoid sensitivity in these subjects...
  77. doi request reprint Rapid effect of inhaled ciclesonide in asthma: a randomized, placebo-controlled study
    Edward M Erin
    National Heart and Lung Institute Clinical Studies Unit, Imperial College, London, UK
    Chest 134:740-5. 2008
    ....
  78. pmc Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression
    Kazuhiro Ito
    Airway Disease Section, National Heart and Lung Institute, Imperial College, London SW3 6LY, England, UK
    J Exp Med 203:7-13. 2006
    ..Thus, reduction of HDAC2 plays a critical role in glucocorticoid insensitivity in repressing NF-kappaB-mediated, but not GRE-mediated, gene expression...
  79. ncbi request reprint Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells
    Louise E Donnelly
    Department of Thoracic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London, United Kingdom
    Am J Respir Cell Mol Biol 26:144-51. 2002
    ..The cells were not steroid insensitive because steroids inhibited GM-CSF release. Therefore, although these cells express iNOS under inflammatory conditions, they do not appear to be regulated directly by glucocorticosteroids...
  80. pmc Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages
    Borja G Cosio
    Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, England, UK
    J Exp Med 200:689-95. 2004
    ..Therefore, theophylline might restore steroid responsiveness in COPD patients...
  81. doi request reprint Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients
    Caterina Brindicci
    Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London, UK
    Chest 135:353-67. 2009
    ..NO production is increased in patients with COPD, and the production of NO under oxidative stress conditions generates reactive nitrogen species that may amplify the inflammatory response in COPD...
  82. pmc A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression
    Kazuhiro Ito
    Thoracic Medicine, Imperial College School of Science, Technology, and Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, United Kingdom
    Proc Natl Acad Sci U S A 99:8921-6. 2002
    ..Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes...
  83. ncbi request reprint NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription
    Kang Yun Lee
    Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Immunol 176:603-15. 2006
    ..Our results suggest that IL-1beta-stimulated transcription of TGF-beta1 is temporally regulated by NF-kappaB and AP-1 and involves histone hyperacetylation at distinct promoter sites...
  84. ncbi request reprint Current and future therapies for airway mucus hypersecretion
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Novartis Found Symp 248:237-49; discussion 249-53, 277-82. 2002
    ..However, the clinical benefits from inhibiting mucus hypersecretion are still not certain, casting some doubts on this therapeutic approach...
  85. ncbi request reprint Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease
    Sarah V Culpitt
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
    Am J Respir Crit Care Med 165:1371-6. 2002
    ..These results suggest that theophylline has antiinflammatory properties that may be useful in the long-term treatment of COPD...
  86. ncbi request reprint Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
    Rachel C Tennant
    Clinical Studies Unit, National Heart and Lung Institute, Imperial College, London, UK
    Curr Opin Pharmacol 3:270-6. 2003
    ..However, because LABAs are given twice daily but tiotropium bromide is required only once daily, the challenge is to develop a combined inhaler that can be employed on a daily basis...
  87. ncbi request reprint Expression and activity of histone deacetylases in human asthmatic airways
    Kazuhiro Ito
    Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY UK
    Am J Respir Crit Care Med 166:392-6. 2002
    ..The increase in HAT activity and reduced HDAC activity in asthma may underlie the increased expression of multiple inflammatory genes, and this is reversed, at least in part, by treatment with inhaled steroids...
  88. ncbi request reprint Corticosteroids: the drugs to beat
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Eur J Pharmacol 533:2-14. 2006
    ..Corticosteroids are likely to remain the mainstay of asthma therapy and new therapeutic strategies may reverse the corticosteroid insensitivity in COPD and severe asthma...
  89. pmc Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma
    Kazuhiro Ito
    Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK
    Am J Respir Cell Mol Biol 39:543-50. 2008
    ..We conclude that impaired nuclear recruitment of HDAC2 could be an important mechanism of steroid resistance of the neutrophilic inflammation in exacerbations of asthma. Oxidative stress may contribute to decreased HDAC2 activity...
  90. ncbi request reprint Overcoming steroid insensitivity in smoking asthmatics
    Tehireem Ahmad
    Imperial College London, National Heart and Lung Institute, Airways Disease Section, Dovehouse Street, London, SW3 6LY, UK
    Curr Opin Investig Drugs 9:470-7. 2008
    ..This review summarizes the various hypotheses underlying corticosteroid insensitivity in smoking asthmatics and discusses the development of potential novel therapies based on these concepts...
  91. ncbi request reprint Formoterol attenuates neutrophilic airway inflammation in asthma
    Kittipong Maneechotesuwan
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College London, UK
    Chest 128:1936-42. 2005
    ..While beta2-agonists may affect neutrophil function in vitro, it is uncertain whether they have effects on neutrophilic inflammation in asthmatic patients in vivo...
  92. ncbi request reprint Faster rise of exhaled breath temperature in asthma: a novel marker of airway inflammation?
    Paolo Paredi
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Science, Technology and Medicine, London, United Kingdom
    Am J Respir Crit Care Med 165:181-4. 2002
    ..Asthmatic subjects have elevated Deltae degrees T. This may represent a novel, noninvasive means of measuring airway blood flow and inflammation in asthma...
  93. ncbi request reprint Theophylline: new perspectives for an old drug
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK
    Am J Respir Crit Care Med 167:813-8. 2003
  94. ncbi request reprint p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex
    K Ito
    Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, Dovehouse St, London SW3 6LY, United Kingdom
    J Biol Chem 276:30208-15. 2001
    ..These data also suggest that pharmacological manipulation of specific histone acetylation status is a potentially useful approach for the treatment of inflammatory diseases...
  95. ncbi request reprint Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle
    Matthew C Catley
    National Heart and Lung Institute, Imperial College London, London, United Kingdom
    Mol Pharmacol 70:697-705. 2006
    ..We therefore suggest that IKK inhibitors may be of considerable benefit in inflammatory airways diseases, particularly in COPD or severe asthma, in which corticosteroids are ineffective...
  96. ncbi request reprint Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD
    Trevor T Hansel
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK
    Drugs Today (Barc) 38:585-600. 2002
    ..Based on these promising features, it is likely that tiotropium used alone or in combination with other bronchodilators will emerge as first-line maintenance treatment for patients with airway obstruction due to COPD...
  97. pmc Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease
    Yasuo To
    Airway Disease Section, NHLI Imperial College, London, United Kingdom
    Am J Respir Crit Care Med 182:897-904. 2010
    ..Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids. This has been linked to a reduction of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline...
  98. ncbi request reprint Cytokine-directed therapies for the treatment of chronic airway diseases
    Peter J Barnes
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK
    Cytokine Growth Factor Rev 14:511-22. 2003
    ....
  99. ncbi request reprint Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation?
    Giovanna E Carpagnano
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK
    Chest 125:2005-10. 2004
    ..The pH of exhaled breath condensate (EBC) is a promising marker. Although pH has been measured in the EBC of adults with inflammatory airway diseases, no study has measured this in children...
  100. ncbi request reprint p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma
    Elvis Irusen
    Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London, United Kingdom
    J Allergy Clin Immunol 109:649-57. 2002
    ..IL-2 combined with IL-4 can alter glucocorticoid receptor (GR) ligand-binding affinity and modulate glucocorticoid function...
  101. ncbi request reprint Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease
    Richard E K Russell
    Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College of Science, London, United Kingdom
    Am J Respir Cell Mol Biol 26:602-9. 2002
    ....